- Angina:
- Transdermal: 1 patch OD
- May be applied to any skin surface, except on extremities below the knees or elbows
- Nitrate-free period of 10-12 hours duration (overnight) needed to prevent tolerance
- Transdermal: 1 patch OD
-
- Injection: Initially IV 5mcg/min
- May be increased by 5mcg/min every 3-5min until response or 20mcg/min IV
- If no response, then may increase by 10-20mcg/min every 3-5min
- Use if unresponsive to SL NTG and beta blockers
- Injection: Initially IV 5mcg/min
- Angina prophylaxis:
- PO 2.6mg-6.4mg every 6-8 hours
- PO 2.6mg-6.4mg every 6-8 hours
- Hypertension:
- IV 5mcg/min
- May increase by 5mcg/min every 3-5min until response OR 20mcg/min
- If no response, then may increase by 10-20mcg/min every 3-5min
- Post-MI heart failure:
- IV 5mcg/min
- May increase by 5mcg/min every 3-5min until response OR 20 mcg/min IV
- If no response, then may increase by 10-20mcg/min every 3-5min
- Tablet:
- 2.6mg
- 6.4mg
- Transdermal patch:
- 5mg
- 10mg
- 15mg
None remarkable
Organic nitrate
It stimulates cGMP production, resulting in vascular smooth muscle relaxation
- Headache
- Dizziness
- Paresthesia
- Weakness
- Flushing
- Rash
- Orthostatic hypotension
- Hypersensitivity
- Recent use (within several days) of PDE-5 inhibitors (e.g, avanafil, sildenafil, tadalafil, or vardenafil) (PO)
- Acute MI (PO)
- Severe anemia
- Increased ICP
- Circulatory collapse
- Shock
- Pericardial tamponade (IV use)
- Restrictive cardiomyopathy (IV use)
- Constrictive pericarditis (IV use)
- Avanafil
- Lidocaine topical
- Prilocaine topical
- Riociguat
- Sildenafil
- Tadalafil
- Vardenafil
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Not recommended |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Nitrocontin | 2.6mg | Tablet | 25’s | Modi Mundipharma | Europa Healthcare |
Nitrocontin | 6.4mg | Tablet | 25’s | Modi Mundipharma | Europa Healthcare |